Lymphoma Breakthrough: Triple Therapy with Venclexta + Obinutuzumab + Bendamustine
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
In the landscape of B-cell malignancies, achieving deep remission (MRD negativity) is a key goal. The triplet combination of Venclexta (Venetoclax), Obinutuzumab, and Bendamustine represents a powerful approach to eradicating residual disease.
1. Synergistic Action
By combining a BCL-2 inhibitor with a next-generation CD20 antibody and chemotherapy, this regimen attacks cancer cells via multiple pathways, showing high rates of MRD negativity in blood and bone marrow.
2. Precision Management in Japan
Japanese hematologists are experts in balancing the efficacy of such intensive regimens with strict infection prophylaxis and safety monitoring. Medical Supporter connects you with Japan's top hematological specialists for personalized care.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.